

DRUG PRIOR AUTHORIZATION COMMITTEE
December 15, 2011
TENTATIVE AGENDA

10:00 - 10:05	Welcome, Announcements and Introductions	Acting Chairman
10:05 - 10:15	Minutes Review	Discussion/ Approval
10:15- 11:15	Pharmacy Program/ Budget Update	Rhonda Driver/ Andrew Haslag
11:15 - 11:20	DUR Update	Rhonda Driver
	<u>Old Business</u>	
11:20 – 11:30	A. Implementation Schedule (Criteria for Previously Approved Clinical Edits, Step Therapies and PA's)	Rhonda Driver
	<u>New Business</u>	
11:30 – 11:45	B. <u>Proposed Actions- New Drug/Product Reviews</u> (See website and Attached Summary) <ul style="list-style-type: none">i. Open Accessii. Clinical Edit/Step Therapyiii. PDL Productsiv. Prior Authorization<ul style="list-style-type: none">• Discussion• Public Hearing• Decision	Rhonda Driver
11:45 – 1:00	C. <u>Clinical Edits</u> <ul style="list-style-type: none">i. Vivitrol Clinical Edit<ul style="list-style-type: none">• Discussion• Public Hearing• Decisionii. SNRI Clinical Edit<ul style="list-style-type: none">• Discussion• Public Hearing• Decisioniii. Zostavax Clinical Edit<ul style="list-style-type: none">• Discussion• Public Hearing• Decisioniv. Amitiza Clinical Edit<ul style="list-style-type: none">• Discussion• Public Hearing• Decisionv. Ampyra Clinical Edit<ul style="list-style-type: none">• Discussion• Public Hearing• Decision	

- D. Preferred Drug List (PDL)**
- i. Tetracyclines**
 - Discussion
 - Public Hearing
 - Decision
 - ii. Topical Steroids**
 - Discussion
 - Public Hearing
 - Decision
 - iii. NSAIDs**
 - Discussion
 - Public Hearing
 - Decision
 - iv. Cough and Cold Preparations**
 - Discussion
 - Public Hearing
 - Decision

- E. Preferred Drug List**
- i. Process Discussion
 - ii. Therapeutic classes/to be announced at meeting.

1:00

LUNCH

1:15-1:30

Program Utilization Information-ACS Update

Rhonda Driver/
Jennifer Kemp-Cornelius

1:30-1:50

Other Business

- "Top 25" Drugs by Cost
- Clinical Edit Summary Report
- Call Center Statistics

*Informal comments will be accepted from members of the audience at various points in the agenda.
Times noted are approximate, Agenda may move more quickly*

Executive Session

1:50-1:55

Minutes Review

Discussion/Approval

1:55-2:30

Case Reviews

Jenna Twehus

NEXT MEETING: MARCH 22, 2012